Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Clinical trial NCT05812807 · RECRUITING

Trial details

NCT number: NCT05812807
Sponsor: Alliance for Clinical Trials in Oncology
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Anatomic Stage II Breast Cancer AJCC v8 Early Stage Triple-Negative Breast Carcinoma Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8

Start date: 2023-06-14
Primary completion: 2033-05-31
Enrollment: 1295

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.